Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.60 |
| ▸ | CTSV | O60911 | 4/20 | 0.60 |
| ▸ | CTSL | P07711 | 4/20 | 0.60 |
| ▸ | CTSK | P43235 | 6/20 | 0.56 |
| ▸ | MMP13 | P45452 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.42 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6805474 | 0.94 | CTSS (0.65) | CTSSCTSVCTSLCTSKACE | |
| SCHEMBL6803155 | 0.93 | CTSS (0.57) | CTSSCTSVCTSLCTSKROCK2 | |
| SCHEMBL6800920 | 0.92 | CTSS (0.69) | CTSSCTSVCTSLCTSKROCK2 | |
| SCHEMBL5096042 | 0.91 | CTSS (0.57) | CTSSCTSVCTSLCTSKROCK2 | |
| SCHEMBL6802966 | 0.91 | CTSS (0.61) | CTSSCTSVCTSLCTSKTSHR | |
| SCHEMBL6803531 | 0.90 | CTSS (0.60) | CTSSCTSVCTSLCTSKTSHR | |
| SCHEMBL6804078 | 0.90 | CTSS (0.60) | CTSSCTSVCTSLCTSKSMN1; SMN2 | |
| SCHEMBL5138783 | 0.90 | CTSS (0.60) | CTSSCTSVCTSLCTSKTSHR | |
| SCHEMBL4454210 | 0.88 | CTSK (0.56) | CTSSCTSVCTSLCTSKROCK2 | |
| SCHEMBL5253840 | 0.88 | CTSK (0.57) | CTSSCTSVCTSLCTSKROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | GRUNENTHAL GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
| EP-1392319-A2 | HYPOTENSIVE LIPID (PROSTAGLANDIN) AND TIMOLOL COMPOSITIONS AND METHODS OF USING SAME | Allergan, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002096432-A2 | HYPOTENSIVE LIPID (PROSTAGLANDIN DERIVATIVES) AND TIMOLOL COMPOSITIONS AND METHODS OF USING SAME | ALLERGAN, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| WO-1997030710-A1 | NON-ACIDIC CYCLOPENTANE HEPTANOIC ACID, 2-CYCLOALKYL OR ARYLALKYL DERIVATIVES AS THERAPEUTIC AGENTS | VISION PHARMACEUTICALS L.P. (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | CTSS 39/4885CTSV 27/4885CTSL 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.